Patterns of care in patients with asymptomatic stage IV colon cancer: A population-based analysis

IF 3.2 2区 医学 Q1 SURGERY
Surgery Pub Date : 2025-05-20 DOI:10.1016/j.surg.2025.109408
Lauren Weaver MD , Catherine G. Tran MD , Amanda R. Kahl MPH , Alexander Troester MD , Aditi Mishra MD , Ajay Prakash MD, PhD , David Brauer MD , Mary E. Charlton PhD , Imran Hassan MD , Paolo Goffredo MD
{"title":"Patterns of care in patients with asymptomatic stage IV colon cancer: A population-based analysis","authors":"Lauren Weaver MD ,&nbsp;Catherine G. Tran MD ,&nbsp;Amanda R. Kahl MPH ,&nbsp;Alexander Troester MD ,&nbsp;Aditi Mishra MD ,&nbsp;Ajay Prakash MD, PhD ,&nbsp;David Brauer MD ,&nbsp;Mary E. Charlton PhD ,&nbsp;Imran Hassan MD ,&nbsp;Paolo Goffredo MD","doi":"10.1016/j.surg.2025.109408","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Currents guidelines recommend chemotherapy with or without biologic agents for asymptomatic stage IV colon cancer treatment, whereas primary tumor resection is reserved for symptomatic tumors or resectable metastases. However, US treatment patterns are understudied. Our study aims to identify real-world treatment patterns for asymptomatic metastatic colon cancer.</div></div><div><h3>Methods</h3><div>Adults with asymptomatic metastatic colon cancer were identified in the 2014 Surveillance, Epidemiology, and End Results Patterns of Care database and categorized into 6 groups: chemotherapy with or without biologic agents, chemotherapy with or without biologic agents with primary tumor resection and metastasectomy, chemotherapy with or without biologic agents and primary tumor resection alone, primary tumor resection only, no treatment, or other treatments. Multinomial logistic regression was used to examine factors associated with receiving each treatment modality. Cox proportional hazard models were used to assess the relationships between treatments and survival.</div></div><div><h3>Results</h3><div>Among 1,717 weighted patient cases, 28% received chemotherapy with or without biologic agents, 23% chemotherapy with or without biologic agents with primary tumor resection, 12% chemotherapy with or without biologic agents with primary tumor resection and metastasectomy, 12% primary tumor resection only, 23% no treatment, and 2% other treatment. Younger patients were more likely to receive chemotherapy with or without biologic agents with primary tumor resection and metastasectomy than chemotherapy with or without biologic agents alone (odds ratio, 3.32; 95% confidence interval, 1.3–8.6) and less likely to undergo no treatment (odds ratio, 0.05; 95% confidence interval, 0.02–0.17). Patients treated by chemotherapy with or without biologic agents with primary tumor resection and metastasectomy had the greatest median survival of 61 months, whereas those with no treatment had a 1-month median survival.</div></div><div><h3>Conclusion</h3><div>Almost one quarter of patients with asymptomatic stage IV colon cancer received no treatment. Meanwhile, 12% of patients underwent curative systemic and surgical treatment, which was associated with a median survival of 5 years, validating reported outcomes of this approach by institutional studies. These data provide an important benchmark for future interventions pertaining to asymptomatic patients with stage IV colon cancer.</div></div>","PeriodicalId":22152,"journal":{"name":"Surgery","volume":"184 ","pages":"Article 109408"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0039606025002600","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Currents guidelines recommend chemotherapy with or without biologic agents for asymptomatic stage IV colon cancer treatment, whereas primary tumor resection is reserved for symptomatic tumors or resectable metastases. However, US treatment patterns are understudied. Our study aims to identify real-world treatment patterns for asymptomatic metastatic colon cancer.

Methods

Adults with asymptomatic metastatic colon cancer were identified in the 2014 Surveillance, Epidemiology, and End Results Patterns of Care database and categorized into 6 groups: chemotherapy with or without biologic agents, chemotherapy with or without biologic agents with primary tumor resection and metastasectomy, chemotherapy with or without biologic agents and primary tumor resection alone, primary tumor resection only, no treatment, or other treatments. Multinomial logistic regression was used to examine factors associated with receiving each treatment modality. Cox proportional hazard models were used to assess the relationships between treatments and survival.

Results

Among 1,717 weighted patient cases, 28% received chemotherapy with or without biologic agents, 23% chemotherapy with or without biologic agents with primary tumor resection, 12% chemotherapy with or without biologic agents with primary tumor resection and metastasectomy, 12% primary tumor resection only, 23% no treatment, and 2% other treatment. Younger patients were more likely to receive chemotherapy with or without biologic agents with primary tumor resection and metastasectomy than chemotherapy with or without biologic agents alone (odds ratio, 3.32; 95% confidence interval, 1.3–8.6) and less likely to undergo no treatment (odds ratio, 0.05; 95% confidence interval, 0.02–0.17). Patients treated by chemotherapy with or without biologic agents with primary tumor resection and metastasectomy had the greatest median survival of 61 months, whereas those with no treatment had a 1-month median survival.

Conclusion

Almost one quarter of patients with asymptomatic stage IV colon cancer received no treatment. Meanwhile, 12% of patients underwent curative systemic and surgical treatment, which was associated with a median survival of 5 years, validating reported outcomes of this approach by institutional studies. These data provide an important benchmark for future interventions pertaining to asymptomatic patients with stage IV colon cancer.
无症状IV期结肠癌患者的护理模式:基于人群的分析
背景:目前的指南推荐在无症状的IV期结肠癌治疗中联合或不联合生物制剂进行化疗,而原发肿瘤切除则保留给有症状的肿瘤或可切除的转移灶。然而,美国的治疗模式尚未得到充分研究。我们的研究旨在确定无症状转移性结肠癌的现实治疗模式。方法在2014年监测、流行病学和最终结果模式护理数据库中确定成人无症状转移性结肠癌,并将其分为6组:化疗联合或不联合生物制剂,化疗联合或不联合生物制剂并原发肿瘤切除和转移切除术,化疗联合或不联合生物制剂并单独原发肿瘤切除,仅原发肿瘤切除,不治疗,或其他治疗。使用多项逻辑回归来检查与接受每种治疗方式相关的因素。Cox比例风险模型用于评估治疗与生存率之间的关系。结果在1717例加权患者中,28%的患者接受了联合或不联合生物制剂的化疗,23%的患者接受了联合或不联合生物制剂的化疗并原发肿瘤切除,12%的患者接受了联合或不联合生物制剂的化疗并原发肿瘤切除和转移切除术,12%的患者只接受了原发肿瘤切除,23%的患者不接受治疗,2%的患者接受了其他治疗。年轻患者在原发肿瘤切除和转移切除的同时,更有可能接受联合或不联合生物制剂的化疗,而不是单独联合或不联合生物制剂的化疗(优势比,3.32;95%可信区间,1.3-8.6),不接受治疗的可能性较小(优势比,0.05;95%置信区间为0.02-0.17)。在原发肿瘤切除和转移切除的基础上,接受或不接受生物制剂化疗的患者的中位生存期最长,为61个月,而未接受治疗的患者的中位生存期为1个月。结论近1 / 4的无症状IV期结肠癌患者未接受治疗。同时,12%的患者接受了可治愈的全身和手术治疗,中位生存期为5年,机构研究证实了该方法的报道结果。这些数据为未来无症状IV期结肠癌患者的干预提供了重要的基准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Surgery
Surgery 医学-外科
CiteScore
5.40
自引率
5.30%
发文量
687
审稿时长
64 days
期刊介绍: For 66 years, Surgery has published practical, authoritative information about procedures, clinical advances, and major trends shaping general surgery. Each issue features original scientific contributions and clinical reports. Peer-reviewed articles cover topics in oncology, trauma, gastrointestinal, vascular, and transplantation surgery. The journal also publishes papers from the meetings of its sponsoring societies, the Society of University Surgeons, the Central Surgical Association, and the American Association of Endocrine Surgeons.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信